Gene expression profiles as prognostic markers in women with ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 7, 2009, Pages 1205-1213

  Jochumsen, Kirsten M ^a   Tan, Qihua ^a,b   Høgdall, Estrid V ^c   Høgdall, Claus ^c   Kjær, Susanne K ^c   Blaakær, Jan ^d   Kruse, Torben A ^a   Mogensen, Ole ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Rigshospitalet   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Epithelial ovarian cancer; Gene expression profiling; Microarray; Prognosis

Indexed keywords

CARBONYL REDUCTASE; CARNITINE PALMITOYLTRANSFERASE I; CHROMOSOME 6 OPEN READING FRAME 62 PROTEIN; CYTOCHROME B; GENE PRODUCT; INOSITOL MONOPHOSPHATASE DOMAIN CONTAINING 1 PROTEIN; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1 PROTEIN; PHOSPHOGLUCOMUTASE; PROTEIN DNAJ; PROTEIN KINASE FYN; RIBOSOME PROTEIN; RNA; TETRASPANIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CANCER SURVIVOR; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; VALIDITY; ALGORITHM; CANCER STAGING; DNA MICROARRAY; GENETICS; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTION AND FORECASTING; SURVIVAL; SURVIVOR; UTILIZATION REVIEW; VALIDATION STUDY;

ADULT; AGED; ALGORITHMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS; TUMOR MARKERS, BIOLOGICAL;

EID: 73449089836     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3cf55     Document Type: Article

References (62)

1. Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16:4-6.
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.
3. Petignat P, Fioretta G, Verkooijen HM, et al. Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol. 2004;13:181-186.
4. O'Malley CD, Cress RD, Campleman SL, et al. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol. 2003;91:608-615.
5. Munstedt K, Franke FE. Role of primary surgery in advanced ovarian cancer. World J Surg Oncol. 2004;2:32.
6. Stoeckle E, Paravis P, Floquet A, et al. Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14:779-787.
7. Tingulstad S, Skjeldestad FE, Halvorsen TB, et al. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003;101(5 Pt 1):885-891.
8. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559-564.
9. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77-85.
10. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992;44:207-212.
11. Tate S, Hirai Y, Takeshima N, et al. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol. 2005;96:143-149.
12. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000; 283:2260-2265.
13. Johannsson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998;16:397-404.
14. Nicoletto MO, Donach M, De Nicolo A, et al. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev. 2001;27:295-304.
15. Elie C, Geay JF, Morcos M, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer. 2004;91:470-475.
16. Nielsen JS, Jakobsen E, Holund B, et al. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14:1086-1096.
17. van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 1994;47:914-919.
18. Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996; 56:2178-2184.
19. Reles A,Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7:2984-2997.
20. Hogdall EV, Kjaer SK, Blaakaer J, et al. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study. Gynecol Oncol. 2006;100:76-82.
21. Hogdall EV, Kjaer SK, Glud E, et al. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. Anticancer Res. 2003;23:3397-3404. (Pubitemid 36975440)
22. Ikeda K, Sakai K, Yamamoto R, et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer. 2003; 13:776-784.
23. Baekelandt M, Kristensen GB, Nesland JM, et al. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol. 1999;17:2061.
24. Hogdall EV, Ryan A, Kjaer SK, et al. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study. Cancer. 2004;100:2387-2395.
25. Launonen V, Mannermaa A, Stenback F, et al. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet. 2000; 122:49-54.
26. Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol. 2004;95:16-22.
27. Franke FE, Von Georgi R, Zygmunt M, et al. Association between fibronectin expression and prognosis in ovarian carcinoma. Anticancer Res. 2003;23:4261-4267.
28. Dehn H, Hogdall EV, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand. 2003;82:287-293.
29. Yousef GM, Scorilas A, Katsaros D, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol. 2003;21:3119-3126. (Pubitemid 46606293)
30. Hogdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66-73.
31. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22:4700-4710.
32. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11:3686-3696.
33. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005;11:2149-2155.
34. Imbeaud S, Graudens E, Boulanger V, et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res. 2005;33:e56.
35. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3.
36. Schoor O, Weinschenk T, Hennenlotter J, et al. Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques. 2003;35:1192-1201.
37. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001;2:[RESEARCH0032]. Epub August 3, 2001
38. Brown MP, Grundy WN, Lin D, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A. 2000;97:262-267.
39. Ein-Dor L, Kela I, Getz G, et al. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics. 2005;21:171-178.
40. Tan Q, Thomassen M, Jochumsen KM, et al. Gene selection for predicting survival outcomes of cancer patients in microarray studies. Proceedings of CISSE 2007 (International Joint Conferences on Computer, Information, and Systems Sciences, and Engineering). Springer.
41. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2001;98:1176-1181.
42. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238:375-385.
43. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol. 2004;165:397-414.
44. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14-25.
45. Donninger H, Bonome T, Radonovich M, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004;23:8065-8077.
46. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291-3300.
47. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62:4722-4729.
48. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.
49. Jazaeri AA, Yee CJ, Sotiriou C, et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002;94:990-1000.
50. Selvanayagam ZE, Cheung TH, Wei N, et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet. 2004;154:63-66.
51. Bernardini M, Lee CH, Beheshti B, et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia. 2005;7:603-613.
52. Spentzos D, Levine DA, Kolia S, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005;23:7911-7918.
53. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11:6300-6310.
54. Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006;118:1963-1971.
55. Berchuck A, Iversen ES, Lancaster JM, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol. 2004; 190:910-925.
56. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer. 2006;16:1733-1745.
57. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling redicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
58. Jochumsen KM, Tan Q, Holund B, et al. Gene expression in epithelial ovarian cancer: a study of intratumor heterogeneity. Int J Gynecol Cancer. 2007;17:979-985.
59. Khalique L, Ayhan A, Weale ME, et al. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 2007;211:286-295.
60. Jarvinen AK, Hautaniemi S, Edgren H, et al. Are data from different gene expression microarray platforms comparable? Genomics. 2004; 83:1164-1168.
61. Barczak A, Rodriguez MW, Hanspers K, et al. Spotted long oligonucleotide arrays for human gene expression analysis. Genome Res. 2003;13:1775-1785.
62. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439: 353-357